NDANASALSPRAY, METERED
Approved
Mar 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NASAREL (flunisolide) by Teva is clinical pharmacology flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. First approved in 1995.
Drug data last refreshed 3h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NASAREL (flunisolide) is a potent intranasal glucocorticoid spray approved for perennial allergic rhinitis. It works through direct topical anti-inflammatory action on nasal mucous membranes with minimal systemic absorption at recommended doses. The drug demonstrates rapid local efficacy, with symptom improvement typically apparent within days of initiation.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, signaling potential organizational restructuring and smaller brand team capacity.
Mechanism of Action
CLINICAL PHARMACOLOGY Flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. As a glucocorticoid, it is several hundred times more potent than the cortisol standard. Clinical studies with flunisolide have shown therapeutic activity…
Worked on NASAREL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.